Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer
- 1 May 2019
- journal article
- review article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 17 (5) , 506-513
Abstract
Prostate cancer (PCa) represents a significant source of morbidity and mortality for men in the United States, with approximately 1 in 9 being diagnosed with PCa in their lifetime. The role of imaging in the evaluation of men with PCa has evolved and currently plays a central role in diagnosis, treatment planning, and evaluation of recurrence. Appropriate use of multiparametric MRI (mpMRI) and MRI-guided transrectal ultrasound (MR-TRUS) biopsy increases the detection of clinically significant PCa while decreasing the detection of clinically insignificant PCa. This process may help patients with clinically insignificant PCa avoid the adverse effects of unnecessary therapy. In the setting of a known PCa, patients with low-grade disease can be observed using active surveillance, which often includes a combination of prostate-specific antigen (PSA) testing, serial mpMRI, and, if indicated, follow-up systematic and targeted TRUS-guided tissue sampling. mpMRI can provide important information in the posttreatment setting, but PET/CT is creating a paradigm shift in imaging standards for patients with locally recurrent and metastatic PCa. This article examines the strengths and limitations of mpMRI for initial PCa diagnosis, active surveillance, recurrent disease evaluation, and image-guided biopsies, and the use of PET/CT imaging in men with recurrent PCa. The goal of this review is to provide a rational basis for current NCCN Clinical Practice Guidelines in Oncology for PCa as they pertain to the use of these advanced imaging modalities.Keywords
This publication has 73 references indexed in Scilit:
- Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective studyEuropean Radiology, 2013
- Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate CancerClinical Nuclear Medicine, 2012
- Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?European Urology, 2012
- Prostate Cancer Foci Detected on Multiparametric Magnetic Resonance Imaging are Histologically Distinct From Those Not DetectedJournal of Urology, 2012
- Multiparametric 3T Prostate Magnetic Resonance Imaging to Detect Cancer: Histopathological Correlation Using Prostatectomy Specimens Processed in Customized Magnetic Resonance Imaging Based MoldsJournal of Urology, 2011
- Radical retropubic prostatectomy: A review of outcomes and side-effectsActa Oncologica, 2011
- The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysisClinical Radiology, 2008
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate CancerNew England Journal of Medicine, 2003
- Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volumeUltrasound in Medicine & Biology, 1995